Abstract
BACKGROUND: Peptide YY (PYY) is a 36 amino-acid peptide secreted from ileal L cells following meals. The cleaved subpeptide PYY[3–36] is biologically active and may constitute the majority of circulating PYY-like immunoreactivity. The peptide family that includes PYY, pancreatic peptide and neuropeptide Y is noted for its orexigenic effect following intracerebroventricular administration.
OBJECTIVE: To investigate the effects of peripheral (intraperitoneal and chronic subcutaneous) infusions of PYY[3–36] on food intake, body weight and glycemic indices.
DESIGN/RESULTS: Food intake was measured in normal mice and in several rodent models of obesity and type II diabetes. In marked contrast to the reported central orexigenic effects, in the present study, PYY[3–36] acutely inhibited food intake by up to 45%, with an ED50 of 12.5 μg/kg in fasted female NIH/Swiss mice. A 4-week infusion reduced weight gain in female ob/ob mice, without affecting the cumulative food intake. In diet-induced obese male mice, PYY[3–36] infusion reduced cumulative food intake, weight gain and epididymal fat weight (as a fraction of carcass) with similar ED50's (466, 297 and 201 μg/kg/day, respectively) and prevented a diet-induced increase in HbA1c. Infusion at 100 μg/kg/day for 8 weeks in male fa/fa rats reduced the weight gain (288±11 vs 326±12 g in saline-infused controls; P<0.05), similar to effects in a pair-fed group. In female ob/ob and db/db mice, there was no acute effect of PYY[3-36] on plasma glucose concentrations. In male diabetic fatty Zucker rats, PYY[3–36] infused for 4 weeks reduced HbA1c and fructosamine (ED50's 30 and 44 μg/kg/day).
CONCLUSION: Peripheral PYY[3–36] administration reduced the food intake, body weight gain and glycemic indices in diverse rodent models of metabolic disease of both sexes. These findings justify further exploration of the potential physiologic and therapeutic roles of PYY[3–36].
Similar content being viewed by others
References
Adrian TE, Bacarese-Hamilton AJ, Smith HA, Chohan P, Manolas KJ, Bloom SR . Distribution and postprandial release of porcine peptide YY. J Endocrinol 1987; 113: 11–14.
Adrian TE, Ferri GL, Bacarese-Hamilton AJ, Fuessl HS, Polak JM, Bloom SR . Human distribution and release of a putative new gut hormone, peptide YY. Gastroenterology 1985; 89: 1070–1077.
Eberlein GA, Eysselein VE, Schaeffer M, Layer P, Grandt D, Goebell H, Niebel W, Davis M, Lee TD, Shively JE . A new molecular form of PYY: structural characterization of human PYY(3–36) and PYY(1–36). Peptides 1989; 10: 797–803.
Grandt D, Schimiczek M, Beglinger C, Layer P, Goebell H, Eysselein VE, Reeve Jr JR . Two molecular forms of peptide YY (PYY) are abundant in human blood: characterization of a radioimmunoassay recognizing PYY 1–36 and PYY 3–36. Regul Pept 1994; 51: 151–159.
Clark JT, Kalra PS, Crowley WR, Kalra SP . Neuropeptide Y and human pancreatic polypeptide stimulate feeding behavior in rats. Endocrinology 1984; 115: 427–429.
Clark JT, Sahu A, Kalra PS, Balasubramaniam A, Kalra SP . Neuropeptide Y (NPY)-induced feeding behavior in female rats: comparison with human NPY ([Met17]NPY), NPY analog ([norLeu4]NPY) and peptide YY. Regul Pept 1987; 17: 31–39.
Morley JE, Levine AS, Grace M, Kneip J . Peptide YY (PYY), a potent orexigenic agent. Brain Res 1985; 341: 200–203.
Marsh DJ, Hollopeter G, Kafer KE, Palmiter RD . Role of the Y5 neuropeptide Y receptor in feeding and obesity. Nat Med 1998; 4: 718–721.
Kanatani A, Mashiko S, Murai N, Sugimoto N, Ito J, Fukuroda T, Fukami T, Morin N, MacNeil DJ, Van der Ploeg LH, Saga Y, Nishimura S, Jhara M . Role of the Y1 receptor in the regulation of neuropeptide Y-mediated feeding: comparison of wild-type, Y1 receptor-deficient, and Y5 receptor-deficient mice. Endocrinology 2000; 141: 1011–1016.
Batterham RL, Cowley MA, Small CJ, Herzog HH, Cohen MA, Dakin CL, Wren AM, Kennedy AR, Low MJ, Ghatei MA, Cone RD, Bloom SR . PYY[3–36], a gut hormone, physiologically inhibits food intake in rodents and man. Proc Endocr Soc 2002. OR 44-1.
Batterham RL, Cohen MA, Ellis SM, Le Roux CW, Withers DJ, Frost GS, Ghatei MA, Bloom SR . Inhibition of food intake in obese subjects by peptide YY3-36. N Engl J Med 2003; 349: 941–948.
Bhavsar S, Hoyt J, Paterniti JR . Continuous infusion of PYY reduces food consumption and body weight in Fatty Zucker (fa/fa) rats. Diabetes 2002; 51 (Suppl 1): A602.
Hoyt J, Bhavsar S, Young AA . Effect of continuous infusion of PYY[3–36] on food intake and body weight in ob/ob (B6VLepob) mice. Diabetes 2002; 51 (Suppl 2): A418 (abstract #1716-P).
Bhavsar S, Parkes D, Hoyt J, Reynolds J, Paterniti JR, Young AA . PYY decreases food consumption and improves glycemic control in Zucker Diabetes Fatty (ZDF) rats. Diabetes 2002; 51 (Suppl 1): A418–A419.
Moore C, Jodka C, Dang JT, Lwin A, Young A . Chronic administration of PYY reduces body weight and improves glycemic control in C57BL/6J mice fed a high fat diet. Diabetes 2002; 51 (Suppl 2): A419.
Batterham RL, Cowley MA, Small CJ, Herzog H, Cohen MA, Dakin CL, Wren AM, Brynes AE, Low MJ, Ghatei MA, Cone RD, Bloom SR . Gut hormone PYY[3–36] physiologically inhibits food intake. Nature 2002; 418: 650–654.
Corp ES, Greco B, Powers JB, Bivens CL, Wade GN . Neuropeptide Y inhibits estrous behavior and stimulates feeding via separate receptors in Syrian hamsters. Am J Physiol Regul Integr Comp Physiol 2001; 280: R1061–R1068.
Dumont Y, Fournier A, St-Pierre S, Quirion R . Autoradiographic distribution of Leu31,Pro34 PYY and [PYY3–36] binding sites in the rat brain evaluated with two newly developed Y1 and Y2 receptor radioligands. Synapse 1996; 22: 139–158.
Bird E, Cardone CC, Contreras RJ . Area postrema lesions disrupt food intake induced by cerebroventricular infusions of 5-thioglucose in the rat. Brain Res 1983; 270: 193–196.
Young A, Gedulin B, Srivastava V, Jodka C, Nikoulina S . PeptideYY inhibits gastric emptying via a neuroendocrine pathway that includes the area postrema. Diabetes 2002; 51 (Suppl 2): A405.
Leslie RA, McDonald TJ, Robertson HA . Autoradiographic localization of peptide YY and neuropeptide Y binding sites in the medulla oblongata. Peptides 1988; 9: 1071–1076.
Lynch DR, Walker MW, Miller RJ, Snyder SH . Neuropeptide Y receptor binding sites in rat brain: differential autoradiographic localizations with 125I-peptide YY and 125I-neuropeptide Y imply receptor heterogeneity. J Neurosci 1989; 9: 2607–2619.
Bonaz B, Taylor I, Tache Y . Peripheral peptide YY induces c-fos-like immunoreactivity in the rat brain. Neurosci Lett 1993; 163: 77–80.
Chen CH, Rogers RC . Central inhibitory action of peptide YY on gastric motility in rats. Am J Physiol 1995; 269 (Part 2): R787–R792.
Yang H . Central and peripheral regulation of gastric acid secretion by peptide YY. Peptides 2002; 23: 349–358.
Deng X, Guarita DR, Pedroso MR, Wood PG, Kreiss C, Sved AF, Whitcomb DC . Area postrema lesion alters the effects of peptide YY on 2-DG-stimulated pancreatic exocrine secretion. Dig Dis Sci 2001; 46: 2460–2469.
Deng X, Guarita DR, Pedroso MR, Kreiss C, Wood PG, Sved AF, Whitcomb DC . PYY inhibits CCK-stimulated pancreatic secretion through the area postrema in unanesthetized rats. Am J Physiol Regul Integr Comp Physiol 2001; 281: R645–R653.
Harding RK, McDonald TJ . Identification and characterization of the emetic effects of peptide YY. Peptides 1989; 10: 21–24.
Grill HJ, Kaplan JM . The neuroanatomical axis for control of energy balance. Front Neuroendocrinol 2002; 23: 2–40.
Nikoulina S, Gedulin B, Smith P, Young A . Effect of PYY on gastric acid secretion and gastro protection in rats. Diabetes 2002; 51 (Suppl 2): A590.
Pittner RA, Young AA, Paterniti JR, inventors; Amylin Pharmaceuticals Inc., assignee. Peptide YY, peptide YY agonists for the treatment of metabolic disorders. US Patent Application WO 02/47712 A2, 2000.
Savage AP, Adrian TE, Carolan G, Chatterjee VK, Bloom SR . Effects of peptide YY (PYY) on mouth to caecum intestinal transit time and on the rate of gastric emptying in healthy volunteers. Gut 1987; 28: 166–170.
Pappas TN, Debas HT, Chang AM, Taylor IL . Peptide YY release by fatty acids is sufficient to inhibit gastric emptying in dogs. Gastroenterology 1986; 91: 1386–1389.
Allen JM, Fitzpatrick ML, Yeats JC, Darcy K, Adrian TE, Bloom SR . Effects of peptide YY and neuropeptide Y on gastric emptying in man. Digestion 1984; 30: 255–262.
Pappas TN, Debas HT, Goto Y, Taylor IL . Peptide YY inhibits meal-stimulated pancreatic and gastric secretion. Am J Physiol 1985; 248 (Part 1): G118–G123.
Lloyd KCK, Grandt D, Aurang K, Eysselein VE, Schimiczek M, Reeve JR . Inhibitory effect of PYY on vagally stimulated acid secretion is mediated predominantly by Y-1 receptors. Am J Physiol 1996; 270 (Part 1): G123–G127.
Adrian TE, Savage AP, Sagor GR, Allen JM, Bacarese-Hamilton AJ, Tatemoto K, Polak JM, Bloom SR . Effect of peptide YY on gastric, pancreatic, and biliary function in humans. Gastroenterology 1985; 89: 494–499.
Greeley JR GH, Guo YS, Gomez G, Lluis F, Singh P, Thompson JC . Inhibition of gastric acid secretion by peptide YY is independent of gastric somatostatin release in the rat. Proc Soc Exp Biol Med 1988; 189: 325–328.
Gue M, Junien JL, Reeve Jr JR, Rivier J, Grandt D, Tache Y . Reversal by NPY, PYY and 3–36 molecular forms of NPY and PYY of intracisternal CRF-induced inhibition of gastric acid secretion in rats. Br J Pharmacol 1996; 118: 237–242.
Yoshinaga K, Mochizuki T, Yanaihara N, Oshima K, Izukura M, Kogire M, Sumi S, Gomez G, Uchida T, Thompson JC et al. Structural requirements of peptide YY for biological activity at enteric sites. Am J Physiol 1992; 263 (Part 1): G695–G701.
Guan D, Maouyo D, Taylor IL, Gettys TW, Greeley JR GH, Morisset J . Peptide-YY, a new partner in the negative feedback control of pancreatic secretion. Endocrinology 1991; 128: 911–916.
Hoentjen F, Hopman WP, Jansen JB . Effect of circulating peptide YY on gallbladder motility in response to feeding in humans. Program and Abstracts, Digestive Disease Week, May 20–23, 2001, Atlanta, GA 2001. (abstract 65).
Lutz TA, Del Prete E, Scharrer E . Reduction of food intake in rats by intraperitoneal injection of low doses of amylin. Physiol Behav 1994; 55: 891–895.
Riddle MC . Pramlintide: an agent for glycemic control plus weight control? Diabetes Technol Ther 2002; 4: 63–65.
Ratner RE, Want LL, Fineman MS, Velte MJ, Ruggles JA, Gottlieb A, Weyer C, Kolterman OG . Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated subjects with type 2 diabetes. Diabetes Technol Ther 2002; 4: 51–61.
Hollander PA, Levy P, Fineman MS, Maggs DG, Shen LZ, Strobel SA, Weyer C, Kolterman OG . Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial. Diabetes Care 2003; 26: 784–790.
Young A, Moore C, Herich J, Beaumont K . Chapter 9: Neuroendocrine actions of amylin. In: Poyner D, Marshall I, Brain SD (eds). The CGRP family: calcitonin gene-related peptide (CGRP), amylin, and adrenomedullin. Landes Bioscience: Georgetown, TX; 2000. pp 91–102.
Clark JB, Palmer CJ, Shaw WN . The diabetic Zucker fatty rat. Proc Soc Exp Biol Med 1983; 173: 68–75.
Acknowledgements
We gratefully acknowledge the technical contributions of Julie Hoyt, Jim Reynolds, Jean Dang, Aung Lwin and Giuseppe DelloIacono to the experiments reported herein.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Pittner, R., Moore, C., Bhavsar, S. et al. Effects of PYY[3–36] in rodent models of diabetes and obesity. Int J Obes 28, 963–971 (2004). https://doi.org/10.1038/sj.ijo.0802696
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.ijo.0802696
- Springer Nature Limited
Keywords
This article is cited by
-
Effects of bariatric surgery and dietary intervention on insulin resistance and appetite hormones over a 3 year period
Scientific Reports (2023)
-
The Implication of Gut Hormones in the Regulation of Energy Homeostasis and Their Role in the Pathophysiology of Obesity
Current Obesity Reports (2020)
-
The timing of fasting leads to different levels of food consumption and PYY3–36 in nocturnal mice
Hormones (2020)
-
Changes in levels of peripheral hormones controlling appetite are inconsistent with hyperphagia in leptin-deficient subjects
Endocrine (2014)
-
Administration of the Y2 Receptor Agonist PYY3-36 in Mice Induces Multiple Behavioral Changes Relevant to Schizophrenia
Neuropsychopharmacology (2013)